Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Phase II Reactions: Acetylation Reactions01:24

Phase II Reactions: Acetylation Reactions

Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic Antibacterial Effects of ε‑Poly‑L‑Lysine and Oregano Essential Oil: In Vitro, In Vivo, and In Silico Approaches to Improve Safety and Shelf Life of Strawberries.

Journal of food science·2026
Same author

Mutation-Tolerant Inhibition of HIV-1 Integrase Strand Transfer by Secondary Metabolites from the Endophytic Fungus <i>Alternaria alternata</i> PO4PR2.

Microorganisms·2026
Same author

Network Pharmacology-Guided Identification of <i>Candida albicans</i> Secondary Metabolites as Modulators of HIV Latency via Oncogenic Signaling Pathways.

International journal of molecular sciences·2026
Same author

Investigation of the Anticancer Potential of Thai Blue Sponge via Targeting the PI3K/AKT/SRC Signaling Pathway using Molecular Docking and Dynamic Stimulation.

Cell biochemistry and biophysics·2026
Same author

Targeting the TRIM28-EZH2 Protein-Protein Interface With Cysteine-Reactive Covalent Inhibitors: A Computational Blueprint for Cancer Therapy.

Chemistry & biodiversity·2026
Same author

Unravelling Tinengotinib's Mechanistic Landscape in Triple-Negative Breast Cancer Via Network Pharmacology and in Silico Simulation Techniques.

Cell biochemistry and biophysics·2025

Related Experiment Video

Updated: May 9, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K

A Computational Approach for Designing a Peptide-Based Acetyl-CoA Synthetase 2 Inhibitor: A New Horizon for

Musab Ali1, Ernest Oduro-Kwateng1, Ibrahim Oluwatobi Kehinde1

  • 1Molecular Bio-Computation and Drug Design Research Group, School of Health Sciences, University of KwaZulu Natal, Westville Campus, Durban, South Africa.

Cell Biochemistry and Biophysics
|April 26, 2025
PubMed
Summary

Researchers designed a novel peptide inhibitor, Pep16, for Acetyl-CoA Synthetase 2 (ACSS2), a key target in cancer. Computational methods identified Pep16, showing superior binding affinity and potential as a specific ACSS2 inhibitor for anticancer drug discovery.

Keywords:
ACSS2Anticancer agentsMolecular dockingMolecular dynamics simulationsPeptide inhibitor

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.2K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Related Experiment Videos

Last Updated: May 9, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.2K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Area of Science:

  • Biochemistry
  • Computational Biology
  • Drug Discovery

Background:

  • Acetyl-CoA Synthetase 2 (ACSS2) is highly expressed in various tumors, enhancing malignancy and representing a novel anticancer target.
  • Peptide-derived drugs offer improved selectivity and efficacy compared to traditional therapeutics.

Purpose of the Study:

  • To computationally design a novel peptide inhibitor targeting ACSS2 for potential anticancer applications.
  • To identify a lead peptide candidate with high binding affinity and favorable therapeutic properties.

Main Methods:

  • Generated 3600 peptide sequences based on the ACSS2 nucleotide motif, classifying amino acids into six physiochemical groups.
  • Employed de novo modeling, Support Vector Machine filters, structural predictions, molecular docking, molecular dynamics simulations, and MM/GBSA analysis.
  • Identified Pep16 as the top candidate through rigorous computational screening and validation.

Main Results:

  • Pep16 demonstrated significantly higher binding affinity (91.1 ± 1.6 kcal/mol) compared to a known inhibitor (53.7 ± 0.7 kcal/mol).
  • Molecular dynamics revealed Pep16 enhances ACSS2 conformational variability, occupies a larger binding interface, and forms firm interactions, particularly with key residues like ARG 373, ARG 526, ARG 628, ARG 631, and LYS 632.
  • Pep16 locks the ACSS2 nucleotide pocket, potentially inhibiting ATP binding and catalytic activity.

Conclusions:

  • Pep16 is a promising, specific ACSS2 inhibitor identified through a systematic computational approach.
  • The developed methodology serves as a valuable tool for future peptide-based drug discovery.
  • Further research is warranted to confirm Pep16's therapeutic potential and compare it with existing inhibitors.